Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended 2-dose Regimens of 9vHPV (Gardasil 9) in 9–14 Year Olds vs Standard 3-dose in Young Women
2022-500256-37-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Sep 2022
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (6 arms), sponsored by Merck & Co. Primary endpoints: Geometric Mean Titers of anti-HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at 4 weeks post last vaccination, Percentage of participants with at least 1 solicited injection-site adverse event and 2 more. Planned start Sep 2022; status: authorised.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2022-500256-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500256-37-00.